Details of the Target
General Information of Target
Target ID | LDTP04505 | |||||
---|---|---|---|---|---|---|
Target Name | Tyrosine-protein kinase JAK3 (JAK3) | |||||
Gene Name | JAK3 | |||||
Gene ID | 3718 | |||||
Synonyms |
Tyrosine-protein kinase JAK3; EC 2.7.10.2; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK |
|||||
3D Structure | ||||||
Sequence |
MAPPSEETPLIPQRSCSLLSTEAGALHVLLPARGPGPPQRLSFSFGDHLAEDLCVQAAKA
SGILPVYHSLFALATEDLSCWFPPSHIFSVEDASTQVLLYRIRFYFPNWFGLEKCHRFGL RKDLASAILDLPVLEHLFAQHRSDLVSGRLPVGLSLKEQGECLSLAVLDLARMAREQAQR PGELLKTVSYKACLPPSLRDLIQGLSFVTRRRIRRTVRRALRRVAACQADRHSLMAKYIM DLERLDPAGAAETFHVGLPGALGGHDGLGLLRVAGDGGIAWTQGEQEVLQPFCDFPEIVD ISIKQAPRVGPAGEHRLVTVTRTDNQILEAEFPGLPEALSFVALVDGYFRLTTDSQHFFC KEVAPPRLLEEVAEQCHGPITLDFAINKLKTGGSRPGSYVLRRSPQDFDSFLLTVCVQNP LGPDYKGCLIRRSPTGTFLLVGLSRPHSSLRELLATCWDGGLHVDGVAVTLTSCCIPRPK EKSNLIVVQRGHSPPTSSLVQPQSQYQLSQMTFHKIPADSLEWHENLGHGSFTKIYRGCR HEVVDGEARKTEVLLKVMDAKHKNCMESFLEAASLMSQVSYRHLVLLHGVCMAGDSTMVQ EFVHLGAIDMYLRKRGHLVPASWKLQVVKQLAYALNYLEDKGLPHGNVSARKVLLAREGA DGSPPFIKLSDPGVSPAVLSLEMLTDRIPWVAPECLREAQTLSLEADKWGFGATVWEVFS GVTMPISALDPAKKLQFYEDRQQLPAPKWTELALLIQQCMAYEPVQRPSFRAVIRDLNSL ISSDYELLSDPTPGALAPRDGLWNGAQLYACQDPTIFEERHLKYISQLGKGNFGSVELCR YDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRL VMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESE AHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYEL FTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAP SPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS |
|||||
Target Type |
Successful
|
|||||
Target Bioclass |
Enzyme
|
|||||
Family |
Protein kinase superfamily, Tyr protein kinase family, JAK subfamily
|
|||||
Subcellular location |
Endomembrane system
|
|||||
Function |
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A and STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.
|
|||||
TTD ID | ||||||
Uniprot ID | ||||||
DrugMap ID | ||||||
Ensemble ID | ||||||
HGNC ID | ||||||
ChEMBL ID |
Target Site Mutations in Different Cell Lines
Cell line | Mutation details | Probe for labeling this protein in this cell | |||
---|---|---|---|---|---|
CCK81 | SNV: p.P37A | . | |||
CHL1 | Substitution: p.D130P | . | |||
CMK | SNV: p.A572V | DBIA Probe Info | |||
DAOY | SNV: p.T321N | DBIA Probe Info | |||
DOTC24510 | SNV: p.S504C | . | |||
HCT15 | SNV: p.V963I; p.G987C; p.H1113R | . | |||
HEC1 | SNV: p.L242P | . | |||
HT115 | SNV: p.A573T | . | |||
IGROV1 | SNV: p.M937T | . | |||
Ishikawa (Heraklio) 02 ER | Insertion: p.Q39PfsTer13 SNV: p.H27R |
. | |||
JURKAT | SNV: p.K885E | . | |||
LN18 | SNV: p.W803S | . | |||
LN229 | SNV: p.M1097L | . | |||
MCC13 | SNV: p.W458Ter Substitution: p.S769F |
. | |||
NCIH1155 | SNV: p.R210W | . | |||
NCIH661 | SNV: p.E698K | . | |||
REH | SNV: p.A280V | . | |||
RPMI8226 | SNV: p.S789L | DBIA Probe Info | |||
SKMEL24 | SNV: p.L1073I | . | |||
SKMEL28 | SNV: p.P693L | . | |||
SUPT1 | Insertion: p.Q39PfsTer13 SNV: p.R272H;p.R403H |
DBIA Probe Info | |||
SW1271 | SNV: p.A1079D | . | |||
TE10 | SNV: p.Q932H | . | |||
TYKNU | SNV: p.Q13H | . | |||
U937 | SNV: p.M511I | DBIA Probe Info |
Probe(s) Labeling This Target
ABPP Probe
Probe name | Structure | Binding Site(Ratio) | Interaction ID | Ref | |
---|---|---|---|---|---|
DBIA Probe Info |
![]() |
C934(7.28); C1048(17.38); C227(442.70) | LDD0209 | [1] | |
IA-alkyne Probe Info |
![]() |
C934(0.00); C1048(0.00) | LDD0166 | [2] | |
NAIA_4 Probe Info |
![]() |
N.A. | LDD2226 | [3] |
Competitor(s) Related to This Target
The Interaction Atlas With This Target
The Protein(s) Related To This Target
Other
The Drug(s) Related To This Target
Approved
Phase 3
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Asp-015k | Small molecular drug | D06EIC | |||
Vx-509 | Small molecular drug | D04QWQ | |||
Pf-06651600 | . | D02TUL |
Phase 2
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Ati-501 | Small molecular drug | D6INZ9 | |||
Ati-502 | Small molecular drug | D6N5UC | |||
Cerdulatinib | . | D0BI3N |
Phase 1
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Sna-125 | . | D0Q0IM |
Investigative
Patented
Discontinued
Drug Name | Drug Type | External ID | |||
---|---|---|---|---|---|
Ag490 | Small molecular drug | D0GZ7B | |||
Pnu156804 | Small molecular drug | D0Z1HQ | |||
R348 | . | D01XEQ |
References